{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:51:41Z","timestamp":1772844701952,"version":"3.50.1"},"reference-count":44,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2020,12,30]]},"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>The aim of this study was to describe the testing rate and frequency of molecular alterations observed in the Lung Cancer Biomarker Testing Registry (LungPath).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A descriptive study of NSCLC biomarker determinations collected from March 2018 to January 2019, from 38 Spanish hospitals, was carried out. Only adenocarcinoma and not otherwise specified histologies were included for epidermal growth factor receptor (\n                      <jats:italic>EGFR<\/jats:italic>\n                      ), anaplastic lymphoma kinase (\n                      <jats:italic>ALK<\/jats:italic>\n                      ), c-ros oncogene 1 (\n                      <jats:italic>ROS1<\/jats:italic>\n                      ) and programmed death ligand-1 (PD-L1) expression. The testing rate and the positivity rate were calculated. Multivariate logistic regression was used to explore the joint relationship between independent explanatory factors and both testing and positivity rates. Two models were adjusted: one with sample type and histology as independent factors, and the other adding the testing rate or the positivity rate of the other biomarkers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      3226 patient samples were analysed, where\n                      <jats:italic>EGFR<\/jats:italic>\n                      ,\n                      <jats:italic>ALK<\/jats:italic>\n                      ,\n                      <jats:italic>ROS1<\/jats:italic>\n                      and PD-L1 information was collected (a total of 12\u2009904 determinations). Overall, 9118 (71.4%) determinations were finally assessed.\n                      <jats:italic>EGFR<\/jats:italic>\n                      (91.4%) and\n                      <jats:italic>ALK<\/jats:italic>\n                      (80.1%) were the mainly tested biomarkers. Positivity rates for\n                      <jats:italic>EGFR<\/jats:italic>\n                      ,\n                      <jats:italic>ALK<\/jats:italic>\n                      ,\n                      <jats:italic>ROS1<\/jats:italic>\n                      and PD-L1 were 13.6%, 3.4%, 2.0% and 49.2%, respectively. Multivariate models showed a lower testing rate for ALK in surgical pieces, fine-needle aspiration or other types of samples versus biopsies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite the high testing rate in EGFR and ALK in NSCLC, the real-world evidence obtained from the LungPath demonstrates that ROS1 and PD-L1 were not determined in a significant portion of patients. LungPath provides crucial information to improve the coverage in molecular testing in lung cancer, to monitor the positivity rate and the introduction of new biomarker testing in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jclinpath-2020-207280","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T13:21:02Z","timestamp":1615814462000},"page":"193-200","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP)"],"prefix":"10.1136","volume":"75","author":[{"given":"Clara","family":"Salas","sequence":"first","affiliation":[{"name":"Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain"},{"name":"External Quality Asessment (GCP) of the Spanish Society of Pathology (SEAP), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Mart\u00edn-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Mart\u00ednez-Pozo","sequence":"additional","affiliation":[{"name":"External Quality Asessment (GCP) of the Spanish Society of Pathology (SEAP), Madrid, Spain"},{"name":"Pathology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Hern\u00e1ndez-Iglesias","sequence":"additional","affiliation":[{"name":"Quality Control Program, Spanish Society of Pathology (SEAP), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2809-7399","authenticated-orcid":false,"given":"David","family":"Carcedo","sequence":"additional","affiliation":[{"name":"Hygeia Consulting S.A, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Ruiz de Alda","sequence":"additional","affiliation":[{"name":"Roche Farma S.A, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J Francisco","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Roche Farma S.A, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Rojo","sequence":"additional","affiliation":[{"name":"External Quality Asessment (GCP) of the Spanish Society of Pathology (SEAP), Madrid, Spain"},{"name":"IIS-Fundacion Jimenez Diaz University Hospital CIBERONC, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"2025121404270656000_75.3.193.1","doi-asserted-by":"publisher","DOI":"10.1517\/14796694.1.1.37"},{"key":"2025121404270656000_75.3.193.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2012.01.011"},{"key":"2025121404270656000_75.3.193.3","first-page":"287","article-title":"Biomarker-driven approach in cancer therapy","volume":"37","author":"Baird","year":"2015","journal-title":"Medicographia"},{"key":"2025121404270656000_75.3.193.4","first-page":"101","article-title":"Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps","volume":"17","author":"Bailey","year":"2014","journal-title":"Discov Med"},{"key":"2025121404270656000_75.3.193.5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.943860"},{"key":"2025121404270656000_75.3.193.6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5334\/aogh.2419","article-title":"Global epidemiology of lung cancer","volume":"85","author":"Barta","year":"2019","journal-title":"Ann Glob Health"},{"key":"2025121404270656000_75.3.193.7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaoncol.2015.0735","article-title":"The global burden of cancer 2013","volume":"1","author":"Fitzmaurice","year":"2015","journal-title":"JAMA Oncol"},{"key":"2025121404270656000_75.3.193.8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/187446720701150105171219","article-title":"Molecular testing and personalized treatment of lung cancer","volume":"7","author":"Sampsonas","year":"2014","journal-title":"Curr Mol Pharmacol"},{"key":"2025121404270656000_75.3.193.9","unstructured":"SEAP IAP . Libro Blanco de la Anatom\u00eda Patol\u00f3gica en Espa\u00f1a, 2019. Available: https:\/\/www.seap.es\/documents\/10157\/1760706\/Libro_Blanco_Anatomia_Patologica_2019.pdf\/87fe0625-9dc9-4170-a0ea-353d1cf06a66"},{"key":"2025121404270656000_75.3.193.10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3747\/co.25.3867","article-title":"Standardizing biomarker testing for Canadian patients with advanced lung cancer","volume":"25","author":"Melosky","year":"2018","journal-title":"Curr Oncol"},{"key":"2025121404270656000_75.3.193.11","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s12094-019-02218-4","article-title":"Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a national consensus of the Spanish Society of pathology and the Spanish Society of medical oncology","volume":"22","author":"Garrido","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"2025121404270656000_75.3.193.12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy275"},{"key":"2025121404270656000_75.3.193.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612674"},{"key":"2025121404270656000_75.3.193.14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00088","article-title":"Brain metastases in Oncogene-Addicted non-small cell lung cancer patients: incidence and treatment","volume":"8","author":"Remon","year":"2018","journal-title":"Front Oncol"},{"key":"2025121404270656000_75.3.193.15","first-page":"14","article-title":"Recomendaciones para La determinaci\u00f3n de biomarcadores en El carcinoma de pulm\u00f3n no microc\u00edtico avanzado. Consenso nacional de la Sociedad Espa\u00f1ola de Anatom\u00eda Patol\u00f3gica Y de la Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica","volume":"45","author":"G\u00f3mez","year":"2012","journal-title":"Rev Esp Patol"},{"key":"2025121404270656000_75.3.193.16","unstructured":"European Medical Agency . European public assessment report de Alecensa\u00ae (alectinib), 2018. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/004164\/WC500241099.pdf"},{"key":"2025121404270656000_75.3.193.17","unstructured":"Issuu . IASLC atlas of ALK testing in Lung cancer - Spanish translation by IASLC - issuu, 2020. Available: https:\/\/issuu.com\/iaslc\/docs\/alk_atlas_spanish_lo-res_final\/54"},{"key":"2025121404270656000_75.3.193.18","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jsps.2018.04.010","article-title":"A comprehensive review on Brigatinib - A wonder drug for targeted cancer therapy in non-small cell lung cancer","volume":"26","author":"Bedi","year":"2018","journal-title":"Saudi Pharm J"},{"key":"2025121404270656000_75.3.193.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3302"},{"key":"2025121404270656000_75.3.193.20","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.8065","article-title":"Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACS\u00e9 phase II trial","volume":"33","author":"Moro-Sibilot","year":"2015","journal-title":"J Clin Oncol"},{"key":"2025121404270656000_75.3.193.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406766"},{"key":"2025121404270656000_75.3.193.22","doi-asserted-by":"crossref","first-page":"S1004","DOI":"10.1016\/j.jtho.2019.08.2213","article-title":"EP1.09-17 Spanish lung cancer biomarker testing registry (Lungpath): descriptive analysis focus in ALK Traslocation results","volume":"14","author":"Lopez","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2025121404270656000_75.3.193.23","doi-asserted-by":"crossref","DOI":"10.1093\/database\/bax082","article-title":"Biomarker identification of hepatocellular carcinoma using a methodical literature mining strategy","volume":"2017","author":"Chang","year":"2017","journal-title":"Database"},{"key":"2025121404270656000_75.3.193.24","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq306"},{"key":"2025121404270656000_75.3.193.25","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/1724600819836097","article-title":"Cancer registries - guardians of breast cancer biomarker information: A systematic review","volume":"34","author":"Voith von Voithenberg","year":"2019","journal-title":"Int J Biol Markers"},{"key":"2025121404270656000_75.3.193.26","unstructured":"Aazmi O , Akhtari M , Amnekar R . Epigenetic biomarkers in Cance. In: Sharma S , ed. Prognostic epigenetics. 15. 1st edition. London: Elsevier Inc, 2019."},{"key":"2025121404270656000_75.3.193.27","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.4"},{"key":"2025121404270656000_75.3.193.28","doi-asserted-by":"publisher","DOI":"10.1177\/1177271917715236"},{"key":"2025121404270656000_75.3.193.29","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3775"},{"key":"2025121404270656000_75.3.193.30","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.21037\/jtd.2018.11.85","article-title":"The challenges of evaluating predictive biomarkers using small biopsy tissue samples and liquid biopsies from non-small cell lung cancer patients","volume":"11","author":"Hofman","year":"2019","journal-title":"J Thorac Dis"},{"key":"2025121404270656000_75.3.193.31","doi-asserted-by":"crossref","first-page":"v918","DOI":"10.1093\/annonc\/mdz394.079","article-title":"Phase II\/III blood first assay screening trial (BFAST) in patients (PTS) with treatment-na\u00efve NSCLC: initial results from the ALK+ cohort","volume":"30","author":"Gadgeel","year":"2019","journal-title":"Ann Oncol"},{"key":"2025121404270656000_75.3.193.32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2011.09.022","article-title":"Establishing an EGFR mutation screening service for non-small cell lung cancer - sample quality criteria and candidate histological predictors","volume":"48","author":"Leary","year":"2012","journal-title":"Eur J Cancer"},{"key":"2025121404270656000_75.3.193.33","first-page":"S607","article-title":"A review of clinical practice guidelines for lung cancer","volume":"5 Suppl 5","author":"von Dincklage","year":"2013","journal-title":"J Thorac Dis"},{"key":"2025121404270656000_75.3.193.34","first-page":"3979","article-title":"Patients with non-small cell lung cancer analyzed for EGFR: adherence to guidelines, prevalence and outcome","volume":"35","author":"Sandelin","year":"2015","journal-title":"Anticancer Res"},{"key":"2025121404270656000_75.3.193.35","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu145"},{"key":"2025121404270656000_75.3.193.36","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2014.00182","article-title":"Non-Small cell lung carcinoma biomarker testing: the pathologist's perspective","volume":"4","author":"Brega","year":"2014","journal-title":"Front Oncol"},{"key":"2025121404270656000_75.3.193.37","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5858\/arpa.2017-0208-RA","article-title":"Cytology smears in the era of molecular biomarkers in non-small cell lung cancer: doing more with less","volume":"142","author":"Lozano","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"2025121404270656000_75.3.193.38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0318"},{"key":"2025121404270656000_75.3.193.39","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000341381","article-title":"EML4-Alk rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer","volume":"83","author":"Wang","year":"2012","journal-title":"Oncology"},{"key":"2025121404270656000_75.3.193.40","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2011-0321-OA"},{"key":"2025121404270656000_75.3.193.41","doi-asserted-by":"crossref","first-page":"461","DOI":"10.21037\/tlcr.2019.08.05","article-title":"Lung cancer in Spain: information from the thoracic tumors registry (TTR study)","volume":"8","author":"Provencio","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"2025121404270656000_75.3.193.42","doi-asserted-by":"crossref","first-page":"887","DOI":"10.21037\/tlcr.2020.04.07","article-title":"Lung cancer biomarker testing: perspective from Europe","volume":"9","author":"Thunnissen","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"2025121404270656000_75.3.193.43","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.e21152","article-title":"The Caris registry: building a biomarker-focused database to advance patient care","volume":"30","author":"Sanders","year":"2012","journal-title":"J Clin Oncol"},{"key":"2025121404270656000_75.3.193.44","doi-asserted-by":"publisher","DOI":"10.1586\/erm.12.59"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2020-207280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T12:27:19Z","timestamp":1765715239000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2020-207280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2,17]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/jclinpath-2020-207280"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2020-207280","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]}}}